Wallis R, Moore G R, Kleanthous C, James R
Molecular and Microbiology Sector, School of Biological Sciences, University of East Anglia, Norwich, England.
Eur J Biochem. 1992 Dec 15;210(3):923-30. doi: 10.1111/j.1432-1033.1992.tb17496.x.
The specificity-determining region of the colicin E9 immunity protein (Im9) for its interaction with its cognate E colicin has been localized to residues 16-43 of the 86-amino-acid protein by the use of gene fusions. A comparison of the alignment of residues in this region of the Im2, Im8 and Im9 proteins have identified nine candidate specificity-determining residues. Using site-directed mutagenesis, we have changed each of these residues in the Im9 protein to the residue found in the same position in the Im8 protein. The immunity phenotype conferred by the mutant immunity protein was then tested. Of the nine residues, only one (Val34 to Asp) showed any evidence of conferring immunity to colicin E8. Changing other residues in the specificity-determining region to the equivalent Im8 residue did not affect the phenotype conferred by the mutant protein, with the exception of the change of Val37 to Glu, which resulted in low-level E8 immunity. While the substitutions at positions 34 and 37 of the Im9 protein introduced immunity towards ColE8, they did not diminish the immunity towards ColE9, suggesting that the two immunity proteins may have a common specificity framework which can be modified by single mutations. In addition, we have used chemical modification of the unique cysteine residue of Im9 (Cys23) in order to probe further this specificity-determining region. Cys23 in the purified Im9 protein is accessible to modification with the thiol-specific reagent 5,5'-dithiobis(2-nitrobenzoic acid) and the stoichiometry of labelling is close to 1:1. This residue, however, cannot be labelled by 5,5'-dithiobis(2-nitrobenzoic acid) when the Im9 protein is complexed to colicin E9. This result is consistent with the Cys23 residue being buried in the complex. However, when the purified Im9 protein modified at Cys23 with a variety of reagents was used in DNase inhibition assays with colicin E9, the modified Im9 proteins still possessed anti-DNase activity but only up to a certain derivative molecular mass. These results are discussed in terms of the proximity of Cys23 to the specificity-determining region.
通过基因融合技术,已将大肠杆菌素E9免疫蛋白(Im9)与其同源大肠杆菌素相互作用的特异性决定区域定位到该86个氨基酸的蛋白质的第16至43位残基。对Im2、Im8和Im9蛋白该区域残基序列的比较鉴定出9个候选特异性决定残基。利用定点诱变技术,我们将Im9蛋白中的每个此类残基替换为Im8蛋白中相同位置的残基。然后对突变免疫蛋白赋予的免疫表型进行了测试。在这9个残基中,只有一个(第34位的缬氨酸替换为天冬氨酸)显示出赋予对大肠杆菌素E8免疫的任何证据。将特异性决定区域中的其他残基替换为等效的Im8残基,除第37位的缬氨酸替换为谷氨酸导致低水平的E8免疫外,均不影响突变蛋白赋予的表型。虽然Im9蛋白第34和37位的替换引入了对ColE8的免疫,但并未降低对ColE9的免疫,这表明这两种免疫蛋白可能具有一个可通过单个突变进行修饰的共同特异性框架。此外,我们对Im9的独特半胱氨酸残基(Cys23)进行了化学修饰,以进一步探究该特异性决定区域。纯化的Im9蛋白中的Cys23可被硫醇特异性试剂5,5'-二硫代双(2-硝基苯甲酸)修饰,标记化学计量比接近1:1。然而,当Im9蛋白与大肠杆菌素E9形成复合物时,该残基不能被5,5'-二硫代双(2-硝基苯甲酸)标记。这一结果与Cys23残基被埋在复合物中一致。但是,当用各种试剂对Cys